MedTrace Logo

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

NCT04783766 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-01-24

No results posted yet for this study

Summary

The purposes of this study are to:

1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects.
2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses.
3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses.
4. Determine the effect of doses of CK-3773274 on the pumping function of the heart.
5. Evaluate the effect CYP2D6 genetic polymorphisms on how the body metabolizes CK-3773274.

Conditions

Interventions

DRUG

CK-3773274

CK-3773274- Tablets

DRUG

Placebo

Placebo- Tablets

Sponsors & Collaborators

  • Cytokinetics

    collaborator INDUSTRY

  • Corxel Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chen, MD · Corxel Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-10
Primary Completion
2021-08-05
Completion
2021-08-05
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04783766 on ClinicalTrials.gov